Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy.
Flowers
M A
MA
University of Toronto, Ontario, Canada.
Heathcote
J
J
Wanless
I R
IR
Sherman
M
M
Reynolds
W J
WJ
Cameron
R G
RG
Levy
G A
GA
Inman
R D
RD
D002353:Carrier State / Q000276:immunology*; D005260:Female; D006509:Hepatitis B / Q000209:etiology* / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D013375:Substance Withdrawal Syndrome / Q000276:immunology / Q000382:microbiology*; D014775:Virus Activation / Q000187:drug effects* / Q000276:immunology
D008727:Methotrexate